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Although it is generally accepted that a malignant transient pleural transudate may appear during the early stages of lymphatic
obstruction, cases demonstrating such probability are rare in literature. A 67-year-old woman was admitted to hospital because
a lymphangitic carcinomatosis and a transudative infrapulmonary pleural eﬀusion with a cytology positive for adenocarcinoma.
One month later the eﬀusion keeps being positive for adenocarcinoma but exudative in character. Lymphatic obstruction appears
as the cause of the initial transudative characteristics of the pleural eﬀusion.
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1.Introduction
Although it is generally accepted that a malignant transient
pleuraltransudatemayappearduringtheearlystagesoflym-
phatic obstruction [1], cases demonstrating such probability
are rare in literature. In fact, as far as we know, the only
one case supporting the possibility that a malignancy alone
may lead to a transient transudative eﬀusion was published
recently by our group [2]. A new similar case, although with
some diﬀerences that could help to understand some still
obscure physiopathological aspects, comes to reaﬃrm the
possible occurrence of this type of transudative eﬀusion.
2.CaseReport
A nonsmoking 67-year-old woman, diagnosed of
noninsulin-dependent diabetes mellitus 20 years before,
was admitted to the hospital because cough, progressive
dyspnea of 4 months of duration, and recently (one week)
left pleural chest pain. At admission, she was no febrile,
with a heart rate of 74beats/min and a respiratory rate
of 20breaths/min. Chest auscultation was normal. No
evidence of jugular venous distension or hepatomegaly was
found. Arterial blood gas ( FIO2 0.21) results were pH 7.39;
PaCO2 42mmHg, PaCO2 78mmHg. Laboratory results were
haemoglobin 12.7g/dL, leukocytes 6660/mm3 , erythrocyte
sedimentation rate 31mm/h, creatinine 0.7mg/dL, glucose
141mg/dL, aspartate aminotransferase 20U/L, alanine
aminotransferase 18U/L, gamma-glutamyltranspeptidase
22U/L, lactic dehydrogenase (LDH) 428U/L, serum
carcinoembrionary antigen (CEA) 135ng/mL. An
echocardiography showed a small pericardial eﬀusion
and mild pulmonary hypertension without evidence of left
ventriculardysfunction.Achestradiographrevealedbilateral
pulmonary interstitial pattern and a left infrapulmonary
pleural eﬀusion. A thoracic high-resolution-computed
tomography scan showed bilateral diﬀuse thickening
of interlobular and perivascular septa compatible with
lymphangitic carcinomatosis and a small (2cm) poorly
deﬁned nodule in the right lower lobe (RLL). A small
left pleural and pericardial eﬀusions were also evident
together with small (1cm) prevascular and para- tracheal
adenopathies (Figure 1). A left thoracentesis yielded light
yellow pleural ﬂuid with biochemical characteristics of
at r a n s u d a t i v ee ﬀusion that was positive for malignancy
on cytological examination. Simultaneous serum and
pleural ﬂuid laboratory data are shown in Table 1.A nR L L




Figure 1: (a) Chest X-ray with interstitial pattern; (b) thoracic high-resolution CT with septal thickening and small left pleural eﬀusion; (c)





Figure 2: (a) Lymphovascular invasion of lung tissue by adenocarcinoma cells H&E×200; (b) adenocarcinoma cell in transudative pleural
eﬀusion. Cell cluster showing variation in nuclear size, prominent nucleoli and vacuolated cytoplasms. Papanicolaou stain×400.
by an adenocarcinoma (Figure 2). A mammography,
gastroscopic, and barium enema studies were all negative
for malignancy. While looking for a deﬁnitive origin of the
primitive tumour, that ﬁnally was considered to be the RLL
pulmonary nodule, the patient did not consent the initiation
of the chemotherapy until 1 month later. Pleural ﬂuid
obtained by a left thoracentesis the day before the initiation
of that therapy was then an exudate (Table 1), while
pleural cytology kept being positive for adenocarcinoma
cells (Figure 2). The patient was treated with 6 cycles of
carboplatin, gencitabine, and docetaxel. After a partial
response with disappearance of the pleural eﬀusion, theCase Reports in Medicine 3
Table 1: Pleural ﬂuid changes between both thoracocenteses.
16/07/03 07/08/03
Cholesterol mg/dL 26 67
Proteins g/dL PF 1.1 4.1
Proteins g/dL S 7.6 6.8
Proteins PF/S 0.14 0.6
LDH U/L PF 49 461
LDH U/L S 504 514
LDH PF/S 0.1 0.8
Albumin g/dL PF 2.89 2.63
Albumin g/dL S 4.31 3.57
Albumin gradient 1.4 0.9
CEA ng/mL 278 267
Erythrocytes 1760 1480
Cytology + +
S: serum; PF: pleural ﬂuid
malignant process progressed, with bone (Figure 1)a n d
brain metastasis and died 11 months after the initiation of
the chemotherapy.
3. Discussion
Several potential causes could explain the rarity of tran-
sudates due to malignant lymphatic obstruction published
previously in literature. The short lived period of the
transudative features of the eﬀusion, its small size, and the
necessity of repeating the diagnostic thoracentesis to demon-
strate its changing character, appear as the more probable
ones. On the other hand, the presence of a lymphangitic
carcinomatosis histologically demonstrated may deter the
practice of a diagnostic thoracentesis.
The delay in the transformation from transudate to
exudate has been ascribed to the necessity of a ﬁnite period
(calculated in few weeks) for the protein to accumulate to
a level greater than 50% of the serum concentration [1].
Otherwise, it may be that extrapleural lymphatic inﬁltration
allowed the development of a transudative eﬀusion before
the tumour invaded the pleural space itself [3]. This last
possibility seems the most probable in the published ﬁrst
case[2],inwhomwithinonemonth,atransudativeeﬀusion,
with a negative pleural ﬂuid cytology, changed to an exudate,
with positive cytology. However, the present case comes
to demonstrate that the malignant lymphatic inﬁltration
can produce a pleural eﬀusion with a positive cytology,
by an obstructive mechanism, without invading the pleural
space itself. This pleural eﬀusion had initially transudative
characteristics until, few weeks later, the protein and LDH
accumulated in the pleural space due to lymphatic obstruc-
tion. The resolution of the eﬀusion simultaneous to that
of the lymphangitic carcinomatosis with the chemotherapy
points out to an obstructive mechanism.
Most pleural transudates in patients with primary or
metastatic pulmonary malignancy are paramalignant that
is due to concomitant diseases such as heart or renal
failure or secondary to pulmonary atelectasis. Published
cases supporting the possibility that a malignancy alone may
lead to a transudative eﬀusion in a patient without any other
apparent cause for a transudate are infrequent [4, 5]. Assi
et al. [4] found that only one of 98 consecutive patients with
a positive pleural cytology had a transudate. The exception
was a patient with simultaneous congestive heart failure.
Afterwards, they concluded that a cytological evaluation for
malignant cells of a transudative pleural eﬀusion is not
recommended. Moreover, they added that patients with a
transudateeﬀusion, even one that is associated with a known
malignant tumour, can have the remaining ﬂuid discarded
and do not require pleural ﬂuid cytology, as the yield is
extremely low [4].
The present case report is an example of an exceptional
situation in which invasive techniques (in particular, pleural
ﬂuid cytology) used at pleural level may obtain an aetiologi-
cal diagnosis in patients with pleural transudative eﬀusions.
When the cytology is done in a transudative eﬀusion
and, the result is positive in absence of alternative causes
of transudate, lymphatic obstruction appears as the most
probable cause and must be ruled out before proceeding to
further pleural invasive explorations.
The Lights criteria have proved to be robust in separating
transudates from exudates with a diagnostic accuracy of
96%. However, this case shows that it is less important
to know the trans- or exudative nature, but more is the
origin/cause of an eﬀusion. We believe that the search
for a better marker of pleural ﬂuid should be focused on
identifying speciﬁc diseases marker and improving clinical
management [6].
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